119 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00006 | Citropin modified peptide-3 | GLFAVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 6 M |
| dbacp00015 | Citropin modified peptide-5 | GLFDVIKAVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp00024 | Citropin modified peptide-7 | GLFDVIKKVAAVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp00103 | Citropin modified peptide-11 | GLFDVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp00112 | Citropin modified peptide-13 | GLFDVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp00121 | Citropin modified peptide-14 | GLFDVIAKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp00155 | Citropin modified peptide-15 | GLFAVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp00188 | Citropin modified peptide-16 | GLFAVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp00222 | Citropin modified peptide-17 | GLFAVIKKVAAVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp00257 | Citropin modified peptide-18 | GLFAVIKKVAAVIRRL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp00266 | Citropin modified peptide-19 | GLFAVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp00275 | Citropin modified peptide-22 | GLFKVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp00297 | Citropin modified peptide-23 | GLFKVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp01257 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Ovary tumor cell line | Ovarian cancer | LC50 : 10-100 µM |
| dbacp01266 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Ovary tumor cell line | Ovarian cancer | LC50 : 10-100 µM |
| dbacp01276 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Ovary tumor cell line | Ovarian cancer | LC50 : 10 µM |
| dbacp01286 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Ovary tumor cell line | Ovarian cancer | LC50 : 10 µM |
| dbacp01297 | Aurein-1.3 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | OVCAR-4 | Ovarian cancer | IC50 : 5 μM |
| dbacp01316 | Aurein-2.5 | MAFLKKSLFLVLFLGLVSLSICEKEKRQNEEDEDENEAANHEEGSEEKRGLFDIVKKVVGAFGSLGKRNDLE | Green and golden bell frog | Not specified | Not specified | Not found | Ovarian cancer | Not found |
| dbacp01325 | Aurein-2.5 | GLFDIVKKVVGAFGSL | Green and golden bell frog | Not specified | Not specified | Not found | Ovarian cancer | Not found |
| dbacp01334 | Aurein-2.5 | GLFDIVKKVVGAFGSL | Green and golden bell frog | Cell membrane disintegration | One-dose and five-dose assay | OVCAR-5 | Ovarian cancer | IC50 : 5 μM |
| dbacp01352 | Aurein-2.7 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | OVCAR-3 | Ovarian cancer | IC50 : 5 μM |
| dbacp01363 | Aurein-3.1 [Cleaved into: Aurein-3.1.1; Aurein-3.1.2] | GLFDIVKKIAGHIAGSI | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | NCI/ADR-RES | Ovarian cancer | IC50 : 5 μM |
| dbacp01376 | Aurein-3.2 | GLFDIVKKIAGHIASSI | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | OVCAR-8 | Ovarian cancer | IC50 : 5 μM |
| dbacp01388 | Aurein-3.3 [Cleaved into: Aurein-3.3.1] | GLFDIVKKIAGHIVSSI | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | IGR-OV1 | Ovarian cancer | IC50 : 5 μM |
| dbacp01411 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Ovary tumor cell line | Ovarian cancer | LC50 : 10 µM |
| dbacp01420 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Ovary tumor cell line | Ovarian cancer | LC50 : 10 µM |
| dbacp01429 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Ovary tumor cell line | Ovarian cancer | LC50 : 10 µM |
| dbacp01532 | BC46 | c[(bA)(bA)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp01537 | BC48 | c[(bA)GRKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp01542 | BC49 | c[(bA)(4aba)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp01547 | BC50 | c[(4aba)(bA)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp01552 | BC70 | c[(bA)(k)RKD(1-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp01557 | BC71 | c[(bA)(k)RKD(2-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp01562 | BC72 | c[(bA)(o)RKD(f)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp01567 | BC74 | c[(bA)(k)(Fguan)KD(f)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp01572 | BC75 | c[(bA)(k)RKD(D-Bip)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp01577 | BC81 | c[(2233tmpa)(k)RKD(2-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp01582 | BC83 | c[(bA)(k)RKD(D-2Anth)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp01587 | BC84 | c[(bA)(k)RKD(w)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp02033 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | IGROV1 | Ovarian cancer | IC50 : 9 µg/ml |
| dbacp02034 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | OVRCAR-3 | Ovarian cancer | IC50 : 15.2 µg/ml |
| dbacp02035 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | OVRCAR-4 | Ovarian cancer | IC50 : 17.6 µg/ml |
| dbacp02036 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | OVRCAR-5 | Ovarian cancer | IC50 : 13.8 µg/ml |
| dbacp02037 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | OVRCAR-8 | Ovarian cancer | IC50 : 13 µg/ml |
| dbacp02038 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 12.6 µg/ml |
| dbacp02362 | Cecropin B | KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL | Silkmoth | Pore formation at the cytoplasmic membrane | MTT/MTS assay | A-2780 | Ovarian cancer | IC50 : 30.6 µM |
| dbacp02364 | Cecropin B | KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL | Silkmoth | Pore formation at the cytoplasmic membrane | MTT/MTS assay | CHO-KI | Ovarian cancer | IC50 : 32 µM |
| dbacp02368 | Cecropin B | KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL | Silkmoth | Pore formation at the cytoplasmic membrane | MTT/MTS assay | A-2780R | Ovarian cancer | IC50 : 34.5 µM |
| dbacp02470 | ChBac3.4 | RFRLPFRRPPIRIHPPPFYPPFRRFL | Goat | Cell necrosis; Inhibiting processes of protein synthesis; Damaging the mitochondrial membrane | TUNEL assay, Reactive oxygen intermediates (ROS) assay | Not specified | Ovarian cancer | Not found |
| dbacp02493 | Citropin 1.1 | GLFDVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp02504 | Citropin 1.1D | glfdvikkvasviggl | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp02578 | CrpC | MNLIEFLQDISIKGWQVWSEGERLCYDAPQEESTALVLAQLKQYKTEILQLLRDRPDILNVYPLSYGQRALWFLWQLAPESHAYNVSFVARICSTVDITAMQKAFEKLIERHPILRTNYPKLGSESIQQVNNFQELNFLQIDASAWSEDELKGKVIESHQQYFDLERGPVMRVRWFTRSKKEHVLLLTIHHIACDAWSLDMLIQELPQLYQVQWADFKTPLSPLKHSYQDYVRWQRNILQETEGERLWNYWQQKLTGDLPALNLATSRQRPPIKTYNGASHHFKLSDKLTKQLKELALNSGATLYMMLLATFQVFLYRYTGQEDILVGSPTSGRSQAKFASILGYFVDPVVMRANLSGNPSFKDFLAQVRQTVLEALAHQDYPFALLVEKLQPHRDPSRSPIFQASFSLLQFQKSQDIQKLFVNQIETYVDWGELKIKPYEIPQQEGQLDLGLEMVEGSSSVFGVFKYNTDLFDESTIERMAGHFQNLLSAIVENPQQKVSESPLLSEVERHQLLVEWNDTAREYPSKCIHQLFEEQVERTPDAVAVVFENQQLTYQQLNQKANQLAHHLLSLRVEPEVLVGIYVERSFEMVVGLLGILKAGGAYVPLDPNYPQERLSYMLADSGVEVLLAQKSLLESLPSHTAQVVCLDSDWGVIEQHSQENLDVGVCSDNLAYVIYTSGSTGVPKGVGIEHFSLCNLIQAQKNLFYLEPNSRVLQFASISFDASVSEIFIALTSGAMLILAIASELIPGSDLKQILQERCVTHVTLPPSALAVLATDEFPALGQIIVAGEACNLELANQWSVGRRLFNGYGPTESTIGAAVAQISHGSEKVTIGRPIANTQIYILDKHLEPVPISVSGELYIGGYGLARGYLNRPELTLEKFIPNPFNSRSKLYKTGDLARYLPDGNIEFLGRLDNQVKIRGFRIELGEIESVLSTHPQVQQVAVTEREDTPGHKRLVAYLVPLQSKEKDPQPQTGIELWPSVAEFYVYDELLYYAMTNDHRRNQSYQVAINQMVKDKVVVEIGTGKDAIIARFCAEAGAKKVYAIERDEQTSKLASACVQELGLSEQIQIIHGDATTANLPEEVDVCVSEIVGPIGGSEGAAVIINNARRFLKSDGVMIPQRSVTQIIAVTLPDELLNQPQFTKVSGYYTQKIFEQVGYPFDLRVCIKGLNQVNWLSNRGVFEDLDFSKLVSTESTHQIKLTIEKSGRLDGFSVGLNLHTIEGECIDILENEHCWLPVYLPVFEPGIYVNEGDIIEAVCTRTLCENNLNPDYTLRGRLLKKTGKEIEFEYISYHWKQLFKQNPFYQRLFAENNLEDYTINKSKPERKVLSSNELRSYLKSKLPEYMLPSSFVILDTLPLTPNGKVDRKALSAPDGEVSREDEYVAPRTEIEQILTNIWQELLLKEQVSIHDNFFEIGGDSILGIQVVSRAKNLGIQITPKQIFQNQTIAKLALVANTTVTVSANQGIVTGVAPLTPIQQWFFAQNSQEAHHYNQSVLLQIPNHLQTELIETALKKLLEHHDALRLRFTSVASEYKQINHGFDDPVAFTVVDLSSTPVIEQPQALSQIATEYQASLNLSEGPLMQVVMFNLGSEVDARLLIIIHHLAVDGVSWRILLSDLETIYQQLIAQQSIQLNAKTTAFIDWAEKLKNYAQSEKIKQELDYWLNQPWSETTPLPLDSAHTQAEKTVDSAINYRVKLSPEETRALLGSVNSAYNTQINDILLSALVVSLAEWTGDSKVLIDLEGHGREELFSDVDLSRTIGWFTSLFPVLLRLPDDKQPAEVIKSIKEQLREIPHRGIGFGILRYLCEDTTVTQKLQTIPTPEISFNYLGQFDQIQSETGWKFAPESTGDNHSSKQTRHHLLEINSLVVEGELQIDWTYSSNFHTHDTVKNLTQSYIQAIKSIIEHCQSENGFGYTASDFPDAQLNQLELDELLKNLGK | Star jelly ATCC 53789 | Triggers the apoptotic cascade | Not specified | Not found | Ovarian cancer | Not found |
| dbacp02579 | CrpD | MSNEEIRRNISSIYPLSPMQQGMLFHSLYAPYSGVYLEQMTWGLKGNINVAAFERAWQKVLDRHSILRTFFVWENRQTPLQVVLKQVNVPWNTLDWRELSSNDQQQQLKQLLQTQREQGFNLSQAPLMRCTLVRLGEDNYKFIWSHHHILMDGWCLSIIFKEILIFYKAHLLGENCQLPKPRPYQDYIAWLNSQDKSAAIEFWQQTLQGFSAPTPLVMDKTQFLKEQQYKTADYQERTSSLSPECTQKLLHIAQQHHVTLSTVVQAAWALLLSRYSGEKDVVFGVTVSGRPPSLSEIEnMVGLFINTLPLRVQVSTQEQLIPWLQKIQQSMVELQEYFYTPLVDIQATSEIPGGIPLFESIVVFENYPIDNSLLNEEGSLHLGDIEVFEQTNYPLTLVAVPGDKLSVRISYDTARFSSNTIEWILGYLQTVLSAIAIVENPSHKVAQLPLLSEVERHQLLVEWNNTATDYPSDKCIHQLFEQQVEKNPNSIAVVFEEEQSTYQQLNQKANQLAHYLQTLGVKPEVLVGICIEYSIDMIVGLLGILKAGGVYVPLDPNYPQERLAFMQEDSNVHIILTQQPLLEKISPQNAHIVCLDRDRDVIAREGVENLDRQTTLDDLAYAIYTSGSTGKPKAVLGTLRGIVNRLHWIWEMLPFGADEICSQKTSINFGDHVAEIFSPLLKGIPLVIVPDDIRGNIPRLMSLLSDRKVTRIVLVPSLLKAILENAPQQLTKLRYLKYVFCSGEVLPLTLAKEFHQKISSARLFNLYGSSEVAADVTCFEVKLRIANQIEAKSKEKLDALKNLPSGSGDRETAVLHKEIIHLQLADERRADLGEALEEYLKRNTIPIGKPISNTQIYILDKYGDLLPPGVTGELYVGGDGLAKGYLNLPELTREKFIPNPFVKDRGKSKKAQAERLFRTGDLARWLPDGNIEFVGRIDHQVKVRGFRIELGEIEAVLSTHPQIQQVVVIAIEDIPGSKRLVAYIVCEDESLSTYHLREFLKQKLPEYMMPSAFVILDTLPLTPSGKIDRKALPAPDGEISREHEYVPPRTSGEEIIANIFASILGVQNVGIHDNFFELGGHSLLATRLISRLRVAFEVEIELSAVFSSPTVAQLEQTLTQLRTTNSALSLPPIQPRTQNQQLPLSFAQDRLWFLNQLEGSSATYnMPGAIRVTGKLDINALQQALSEIVRRHEVLRTSFRTVNGTPIQVIHPEATMNISVADLQQLEATERESVLHQQAQLAAITPFDLETAPLIRCSLLQLDAREYVLLLTMHHIVSDGWSMGIFSQELSTLYQAFSAGKPSPLAELPIQYADFAVWQRQWLSGKVLETQLNYWLSQLEGAPELLQLPTDRPRPTVQTFRGTTQSFSLNTDLKEKLQTLSRNSGTTLFMTLHAAFATLLYRYSGQLDILIGSPIANRNCSEIESLIGFFANTLVLKTRFEDNPSFENLLAQVRETTLEAYEHQDVPFEQVVEVLQPQRSLSYAPLFQVMFVLQNAPMGELELPGVTLNLLSSQTETARFDLTVSMQQTSEALVGSWEYNTDLFDGSTIERMTAHFQNLCSAIVENPQQKISELPLFTDSEQEQVLHSYNNIATTYLLDKYVHFLSSNNLQIYILDNHQQLVPLSVEGEIYLGNCDLLPDKLHPEPEKFISFIEHTQLGKLLKTGEWGCRRVDGSLELLGKEHRIVTVNGQRINLQRIEQALQTAKGVEDCYVMVRNQKLVAYVVKDGSWAREFLHHYLKSQLPGYPLPCIYVPVSALPLTSFGEVDEVGLASISIIDSELINTWEEQIGSQAEIDKVAVFIEPNVKTISPIHLEELLPSIQAIFNQGSTPVETPRTARGKESSSLLEIKSPAISHEEVLIFPESSPETLGEMLQKTAGKFPHKGITYINSDGSEQVQSYAQLLEDAQRILGGFRKLGIKPQDKVILQLKENKDFISAFWGCVLGGFIPVPVVIPVSYDQPNVNLNKLQNSWQMLERPLILTDKKSLSELKKWSQNLNDDNFKLETIESLQKFSTDKDYYNAQPEDLALFMLTSGSTGMSKVVQLSHLNLLSRTIGSIQMNNFTPEDITLNWMPLDHVAGLIYFHIRDIYLGCKQIHATSQLVIEKPLRWLDWIDTFGVTVTFAPNFAYSLINDFVQEIEKQNWNLSSIRLMLNGAEQIVAATARRFLKLLAPFGLPGDAMTPSWGMAEVSSGITYSDNFSLLSSSDDNSFVNLGKPIRGTCLRIVNQDMEVLSEGEIGLLQVKGLTVTSGYYQNPKANKEAFTEDGWFNTGDLGFIKDGCLTITGRQKDIIIINGVNYYSHEIEAVVEELGEVEVSYTAACGVCVASNNTEELVIFFTPYVSEKNQLLELLKKVREQVIKYCGINPSYLIPIDKELIPKTSIGKIQRSLLKQRFECGEFKSLRQRVDLLLDNTNTIPNWFYRKVWQIKESKNTLLNYSSQKTLTLIFTDNLGWQQDNRGMSQTVQPYAQVTIGSNFAQISPNHYSVVPGNPQHYRLLIDSLRQNSQVISQILHLWNYNEQTEKISSLENLESTQQQGIYSLLFLVQALEEIQGKQQAVKLLWIANQSQLVHPTDKIQPEKSTVLGLLKTVSQEMPWLTTRHLDLPLAPELNNSYIWQELYSADKELEVAIRNRERFVSGLEPVDMTAKEKQKIPILPGGTYLLTGGLGGIGTVIAKYLLEHYQANLILVGRTQIEDNNEEASTKLQRYQELEKLPGSIIYQTVDICDLVGLQQVVEKATQEWRTQLDGVFHMAGIIQETPIEKETPGNIAAVLRPKVSGTWVLHQLLKDKENALFVHFCSVNGFFGGTNVAAYSAANSFQSAWSDYQQQNGFQSYCCSWSMWNETGISHGYQFQELSRAKGYFIITPQQGFYSFLAALSGSEHNLLIGLDGTKTNVEHLIRDCQPKQKLTAYFTSPTPELAALSLQELQLHDRFGIPNQINFVQLEQIPLTQRGEINREQIAAIYGGLNTSEQTKPRNQTERQLVEIFQEVLNLPSIGIHDNFFSLGGHSLLAVRLMSEIQQQFQKNLPLATLFQNPTIERLALLVGSDSGAELWSPLVPIQQNGSLPPLFCVPGAGGNVLYFHHLAQYLGNNQPLYGLQAQGLDGETEPHKSVEEIASQHIKAIQTVQPVGPYFLAGHSFGSHVVFEMANQLQLIGKSVAYVGILDTPAPTSQANHQNDFSNWDNAKWICRMAEVIEDIVGENLFLSYETLTSLTWEQQLNYFKQKLEIVGFLPAQTDIKIVRGLLQVFQTQCQIKYEPEKTYKTPITLFCAREINPEQESYSHIFQEPTWGWNQFSDGEVEIHIVPGNHVSMLSEPHVKVLAQQMQISLEQAQKTHQLEK | Star jelly ATCC 53789 | Triggers the apoptotic cascade | Not specified | Not found | Ovarian cancer | Not found |
| dbacp02595 | Cyclic [W(RW)4 ]-Dox | WRWRWRWRW | Not found | Inhibition of the cell proliferation | MTT/MTS assay | SK-OV-3 | Ovarian cancer | 51-74% inhibition of cell proliferation at 1 µM |
| dbacp02968 | FRAP-4 | WEWT | Not found | Inducing apoptosis | Not specified | NOS4 | Ovarian cancer | IC50 : 7 µM |
| dbacp02978 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 27.39 µM |
| dbacp02985 | GA-K3 | FLKWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 24.76 µM |
| dbacp02992 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 :12.55 µM |
| dbacp02999 | GA-K4 | FLKWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 12.55 µM |
| dbacp03006 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 22.06 µM |
| dbacp03013 | GA-W3 | FLGWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 22.06 µM |
| dbacp03020 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 14.58 µM |
| dbacp03027 | GA-W4 | FLWWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | SK-OV-3 | Ovarian cancer | IC50 : 14.58 µM |
| dbacp03158 | GR01 | c[CRKDC]Disulfidebridge | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp03163 | GR16 | c[KRKDF] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp03168 | GR35 | c[KRAAF] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Ovarian cancer | Not found |
| dbacp03644 | Lan-7 | fA*YwKA*T | Analogue of TT-232 | Tubulin depolymerization | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 17.05 ± 6.61 µM |
| dbacp03645 | Lan-7 | fA*YwKA*T | Analogue of TT-232 | Tubulin depolymerization | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 16.93 ± 1.84 µM |
| dbacp03755 | LHRH–BH3 peptide luteinizing hormone-releasing hormone (LHRH) | QHWSYGLRPGMGQVGRQLAIIGDDINRRY | Effectors (BAK, BAX) | Inducing apoptosis | Cytotoxicity assay, MTT assay | SKOV-3 | LHRH negative ovarian cancer | Not found |
| dbacp04104 | linear (RW)4-Dox | RWRWRWRW | Doxorubicin (Dox) is a well-known anthracycline which has been conjugated to a CPP | Inhibition of the cell proliferation | MTT/MTS assay | SK-OV-3 | Ovarian cancer | 28-34% anti-proliferative activity at 1 µM |
| dbacp04150 | LL 37 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | Also known human cathelicidin | Plasma membrane perturbations | MTT/MTS assay | OVRCAR-3 | Ovarian cancer | LC50 : 24 at 100 µM |
| dbacp04449 | Maculatin 1.3 | GLLGLLGSVVSHVVPAIVGHF | Fringed Tree Frog, Australia | Disruption of cancer membrane integrity | Not specified | Not specified | Ovarian cancer | MIC : 1 – 100 µg/ml |
| dbacp04459 | Maculatin 1.4 | GLLGLLGSVVSHVLPAITQHL | Fringed Tree Frog, Australia | Disruption of cancer cell membrane integrity | Not specified | Not specified | Ovarian cancer | MIC : 1 – 100 µg/ml |
| dbacp04468 | Maculatin 1.4 | GLLGLLGSVVSHVLPAITQHL | Fringed Tree Frog, Australia | Disruption of cancer cell membrane integrity | Not specified | Not specified | Ovarian cancer | IC50 : 10−5 - 10−6 M |
| dbacp04518 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Daudi | Ovarian cancer | IC50 : 28 µg/ml |
| dbacp04658 | Melittin-N (MEL-N) (MLT) | MKFLVNVALVFMVVYISYIYAAPEPEPAPEPEAEADAEADPEAGIGAVLKVLTTGLPALINWIKRKRQQG | Indian honeybee | Cytotoxic | MTT assay | SKOV-3 | Ovarian cancer | IC50 : 0.5 μM |
| dbacp04659 | Melittin-N (MEL-N) (MLT) | MKFLVNVALVFMVVYISYIYAAPEPEPAPEPEAEADAEADPEAGIGAVLKVLTTGLPALINWIKRKRQQG | Indian honeybee | Cytotoxic | MTT assay | SKOV-3 | Ovarian cancer | IC50 : 0.25 μM |
| dbacp04660 | Melittin-N (MEL-N) (MLT) | MKFLVNVALVFMVVYISYIYAAPEPEPAPEPEAEADAEADPEAGIGAVLKVLTTGLPALINWIKRKRQQG | Indian honeybee | Cytotoxic | MTT assay | PA-1 | Ovarian cancer | IC50 : 1 μM |
| dbacp04661 | Melittin-N (MEL-N) (MLT) | MKFLVNVALVFMVVYISYIYAAPEPEPAPEPEAEADAEADPEAGIGAVLKVLTTGLPALINWIKRKRQQG | Indian honeybee | Cytotoxic | MTT assay | PA-1 | Ovarian cancer | IC50 : 1 μM |
| dbacp05486 | Pexiganan | GIGKFLKKAKKFGKAFVKILKK | Analog of African clawed frog | Plasma membrane perturbations | MTT/MTS assay | OVRCAR-3 | Ovarian cancer | LC50 : 13 at 100 µM |
| dbacp05939 | Retro | LGGIVSAVKKIVDFLG | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp06142 | SP22 | ACHWPWCHGWHSACDLPMHPMC | Not found | Inducing apoptosis | Tunnel assay | CHO | Ovarian cancer | Not found |
| dbacp06307 | TLS peptide | TLSGAFELSRDK | Not found | Inducing apoptosis | Not specified | SKOV3 | Ovarian cancer | Not found |
| dbacp06323 | TP3 | FIHHIIGGLFSVGKHIHSLIHGH | Nile tilapia | Pore formation on cell membrane | In vitro cytotoxicity assay | Tilapia ovary (TO2) cells | Ovarian cancer | MIC : > 100 µg/ml |
| dbacp06325 | TP4 | FIHHIIGGLFSAGKAIHRLIRRRRR | Gills, Nile Tilapia | Pore formation on cell membrane | In vitro cytotoxicity assay | Tilapia ovary (TO2) cells | Ovarian cancer | MIC : > 100 µg/ml |
| dbacp06611 | Maculatin 1.3 | GLLGLLGSVVSHVVPAIVGHF | Fringed Tree Frog, Australia | Disruption of either cancer or bacterial cell membrane integrity | Not specified | Not specified | Ovarian cancer | IC50 : 10−5 to 10−6 M |
| dbacp06756 | 37-mer peptide | TKEQKEQIAKATGLTTKQVRNWYVQLNASIKVCMCSC | Synthetic | Apoptosis inducing | MTT assay | SK-OV-3 | Ovarian cancer | IC50 = 27.45 ± 1.5085 μM |
| dbacp07026 | [G10a]-SHa | FLSGIVGMLaKLF | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | A-2780 | Ovarian Cancer | IC50 = 14.75 ± 7.35 µM |
| dbacp07033 | [G10a]2-SHa | FLSGIVGMLaKLFKFLKaLMFLSGIVG | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | A-2780 | Ovarian Cancer | IC50 = 4.42 ± 0.06 µM |
| dbacp07040 | [G10a]3-SHa | FLSGIVGMLaKLFFLSGIVGMLaKLFFLSGIVGMLaKLFKK | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | A-2780 | Ovarian Cancer | IC50 = 2.31 ± 0.08 µM |
| dbacp07046 | Jeff-[G10a]2-SHa | FLSGIVGMLaKLF-jeff-FLSGIVGMLaKLF | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | A-2780 | Ovarian Cancer | IC50 = 33.92 ± 5.90 µM |
| dbacp07537 | AEM-28 | LRKLRKRLLRDWLKAFYDKVAEKLKEAF | Synthetic | LPA reduction suppresses tumor growth | MTS assay | OV-2008 | Ovarian Cancer | ~60% cell viability at 10 μg/mL |
| dbacp07538 | AEM-28 | LRKLRKRLLRDWLKAFYDKVAEKLKEAF | Synthetic | LPA reduction suppresses tumor growth | MTS assay | SK-OV-3 | Ovarian Cancer | ~50% cell viability at 10 μg/mL |
| dbacp07543 | AEM-28–2 | Aha-LRRLRRRLLRDWLKAFYDKVAEKLKEAF | Synthetic | LPA reduction suppresses tumor growth | MTS assay | OV-2008 | Ovarian Cancer | ~40% cell viability at 10 μg/mL |
| dbacp07544 | AEM-28–2 | Aha-LRRLRRRLLRDWLKAFYDKVAEKLKEAF | Synthetic | LPA reduction suppresses tumor growth | MTS assay | SK-OV-3 | Ovarian Cancer | ~30% cell viability at 10 μg/mL |
| dbacp07880 | Nubein6.8 | LKCNQLIPPFWKTCPKGKNLCYKMTMRAAPMVPVKRGCIDVCPKSSLLIKYMCCNTDKCN | Naja nubiae | DNA damage and apoptosis induction | MTT assay | A-2780 | Ovarian Cancer | EC50 = 1.249 ± 0.06 μM |
| dbacp07984 | SOR-C13 | KEFLHPSKVDLPR | Synthetic | TRPV6 inhibition suppresses ovarian tumors | IP | SKOV-3 | Ovarian Cancer | Effectively inhibited the growth of tumor |
| dbacp08055 | L-FP21-PEG-PEI/pGRO-α | YTRDLVYGDPARPGIQGTGTF | Synthetic | D-FP21 delivers gene, inhibits proliferation | CCK-8 assay | HO-8910 | Ovarian Cancer | IC50 = 23.4 μg/mL |
| dbacp08056 | D-FP21-PEG-PEI/pGRO-α | ytrdlvygdparpgiqgtgtf | Synthetic | D-FP21 delivers gene, inhibits proliferation | CCK-8 assay | HO-8910 | Ovarian Cancer | IC50 = 21.6 μg/mL |
| dbacp08171 | Peptide - 1 | GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK | Synthetic | Not Available | CellTiter-Glo assay | IGROV-1 | Ovarian Cancer | IC50 > 7.5 µM |
| dbacp08183 | Peptide - 2 | GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR | Synthetic | Not Available | CellTiter-Glo assay | IGROV-1 | Ovarian Cancer | IC50 = 6.0 µM |
| dbacp08191 | Peptide - 3 | GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn | Synthetic | Not Available | CellTiter-Glo assay | IGROV-1 | Ovarian Cancer | IC50 = 5.4 µM |
| dbacp08199 | Peptide - 4 | GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab | Synthetic | Not Available | CellTiter-Glo assay | IGROV-1 | Ovarian Cancer | IC50 = 2.3 µM |
| dbacp08207 | Peptide - 6 | GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK | Synthetic | Not Available | CellTiter-Glo assay | IGROV-1 | Ovarian Cancer | IC50 > 7.5 µM |
| dbacp08215 | Peptide - 7 | GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR | Synthetic | Not Available | CellTiter-Glo assay | IGROV-1 | Ovarian Cancer | IC50 > 7.5 µM |
| dbacp08223 | Peptide - 8 | GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK | Synthetic | Not Available | CellTiter-Glo assay | IGROV-1 | Ovarian Cancer | IC50 > 7.5 µM |
| dbacp08231 | Peptide - 9 | GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK | Synthetic | Not Available | CellTiter-Glo assay | IGROV-1 | Ovarian Cancer | IC50 > 7.5 µM |
| dbacp08239 | Peptide - 10 | GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK | Synthetic | Not Available | CellTiter-Glo assay | IGROV-1 | Ovarian Cancer | IC50 > 7.5 µM |
| dbacp08247 | Peptide - 11 | KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c) | Synthetic | Not Available | CellTiter-Glo assay | IGROV-1 | Ovarian Cancer | IC50 > 7.5 µM |
| dbacp08291 | L-Carnosine | Beta-AH | Synthetic | Not Available | MTT assay | A-2780 | Ovarian Cancer | IC50 = 165 mM |
| dbacp08292 | L-Carnosine | Beta-AH | Synthetic | Not Available | MTT assay | OVCAR-3 | Ovarian Cancer | IC50 = 125 mM |
| dbacp08293 | L-Carnosine | Beta-AH | Synthetic | Not Available | MTT assay | SK-OV-3 | Ovarian Cancer | IC50 = 485 mM |
| dbacp08304 | MAD1 | KRWHWWRRHWVVW | Synthetic | Not Available | MTT assay | OVCAR-3 | Ovarian Cancer | IC50 = 14.2 μM |
| dbacp08306 | MAD1 | KRWHWWRRHWVVW | Synthetic | Not Available | MTT assay | NCI/ADR-RES | Ovarian Cancer | IC50 = 85.6 μM |
| dbacp08308 | DAP1 | LWKRWVGVWRKWL | Synthetic | Not Available | MTT assay | OVCAR-3 | Ovarian Cancer | IC50 = 8.6 μM |
| dbacp08309 | DAP1 | LWKRWVGVWRKWL | Synthetic | Not Available | MTT assay | NCI/ADR-RES | Ovarian Cancer | IC50 = 14.0 μM |
| dbacp08311 | AMP1 | WKWLKKWIK | Synthetic | Not Available | MTT assay | OVCAR-3 | Ovarian Cancer | IC50 = 51.1 μM |
| dbacp08312 | AMP2 | KRWWKWWRR | Synthetic | Not Available | MTT assay | OVCAR-3 | Ovarian Cancer | IC50 = 53.5 μM |